Article Text
Abstract
Introduction The phase 4 Teri-PRO study (NCT01895335) investigated patient-reported outcomes (PROs), effectiveness, safety, and tolerability of teriflunomide in a real-world setting, and included a large proportion of patients with RMS who had received a DMT prior to study entry.
Methods Patients received teriflunomide for 48 weeks, per local labelling. Treatment satisfaction with teriflunomide was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM V1.4). In patients switching from a prior DMT within 6 months (switchers), TSQM was measured at baseline and Week (W)48.
Results Switchers (n=594) reported statistically significant improvements in mean TSQM Global Satisfaction score at W48 vs baseline (p<0.0001). Mean Global Satisfaction improved significantly (p<0.0001) vs baseline in patients switching from injectable DMTs (n=446) or dimethyl fumarate (n=74), and remained stable in patients switching from natalizumab (n=45, p=0.8829) or fingolimod (n=29, p=0.0605). Additional PROs, and data for patients with prior DMT use 6 months–2 years before study entry, will be discussed in the poster.
Conclusions Significant improvements in treatment satisfaction with teriflunomide were reported by patients with prior DMT use within 6 months. Patients switching from injectable DMTs or dimethyl fumarate also reported increased satisfaction with teriflunomide treatment, as measured by the TSQM.
Study supported by Sanofi Genzyme.